Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating adult participants with moderate to severe ulcerative colitis and Crohn's disease. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for treating Atopic dermatitis (AD), psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), ulcerative colitis (UC), and Crohn's disease (CD). Approximately 600 adult participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in Korea. Upadacitinib will be administered in accordance with the terms of the local marketing authorization, and treatment of participants will be determined solely by the investigator. Participants in the study will be followed for up to 52 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Study Type
OBSERVATIONAL
Enrollment
105
SoonChunHyang University Hospital Cheonan /ID# 270015
Cheonan-si, Chungcheongnam-do, South Korea
The Catholic University of Korea, Daejeon St. Mary's Hospital /ID# 267843
Daejeon, Daejeon Gwang Yeogsi, South Korea
Inje University - Ilsan Paik Hospital /ID# 269995
Goyang-si, Gyeonggido, South Korea
Keimyung University Dongsan Hospital /ID# 269775
Daegu, Gyeongsangbuk-do, South Korea
Chosun University Hospital /ID# 269990
Gwangju, Jeonranamdo, South Korea
Kyung Hee University Hospital /ID# 270003
Dongdaemun-gu, Seoul Teugbyeolsi, South Korea
Yonsei University Health System Severance Hospital /ID# 268865
Seoul, Seoul Teugbyeolsi, South Korea
Gangnam Severance Hospital /ID# 270020
Seoul, Seoul Teugbyeolsi, South Korea
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 270014
Seoul, Seoul Teugbyeolsi, South Korea
Hallym University Kangnam Sacred Heart Hospital /ID# 270013
Seoul, Seoul Teugbyeolsi, South Korea
...and 4 more locations
Percentage of participants who reported Serious Adverse Event
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
Time frame: Up to 52 weeks
Percentage of participants who reported Serious Adverse Drug Reaction
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.
Time frame: Up to 52 weeks
Percentage of participants who reported unexpected (not reflected in the latest approved label) Adverse Events/Adverse Drug Reaction
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.
Time frame: Up to 52 weeks
Percentage of participants who reported known (labeled) Adverse Drug Reaction
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.
Time frame: Up to 52 weeks
Percentage of participants who reported non-serious Adverse Event/Adverse Drug Reaction
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.
Time frame: Up to 52 weeks
Percentage of participants who reported the events related to important identified risks/important potential risks/missing information
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. Among AEs, an event whose causal relationship with the product cannot be ruled out is considered an adverse drug reaction.
Time frame: Up to 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.